Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Birchmeier, Walter Prof. Dr. (1) Blüthgen, Nils (1) Chen, Wei Prof. Dr. (1) Chu, Van Trung Dr. (3) Daniel, Peter Prof. Dr. (1) Di Virgilio, Michela Prof. Dr. (1) Graf, Robin Dr. (1) Heinemann, Udo Prof. Dr. (1) Hinz, Michael Dr. (1) Kempa, Stefan Dr. (1) Kühn, Ralf Dr. (2) Landthaler, Markus Prof. Dr. (1) Lusatis, Simone (1) Mastrobuoni, Guido Dr. (1) Rajewsky, Klaus Prof. Dr. (21) Scheidereit, Claus Prof. Dr. (1) Schütz, Anja Dr. (1) Selbach, Matthias Prof. Dr. (1) Wolf, Jana Prof. Dr. (1) Wollert-Wulf, Brigitte (3) Wyler, Emanuel Dr. (1) (-) Janz, Martin Dr. (13) (-) Mathas, Stephan Dr. (17) (-) Biologie maligner Lymphome (21) Genetik und Genomik von Herz- Kreislauferkrankungen (1) (-) Immunregulation und Krebs (1) Molekulare Immunologie und Gentherapie (27) Psychoneuroimmunologie (1) Systembiologie von Gen-regulatorischen Elementen (1) Tumorgenetik und zelluläre Stressantworten (1) 1999 (2) (-) 2000 (2) 2001 (1) 2002 (6) 2003 (3) 2004 (3) 2005 (3) (-) 2006 (5) 2007 (4) 2008 (4) (-) 2009 (4) (-) 2010 (3) 2011 (4) (-) 2012 (2) 2013 (3) 2014 (2) (-) 2015 (5) 2016 (3) 2017 (5) 2018 (2) 2019 (2) 2020 (6) 2021 (3) 2022 (7) 2023 (9) 2024 (3) 21 Ergebnisse: Active Filter: Janz, Martin Dr.Mathas, Stephan Dr.Biologie maligner LymphomeImmunregulation und Krebs200020062009201020122015 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 11. April 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert 01. Juni 2015 / Front Biosci The origins of ALK translocations V. Roukos S. Mathas 15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas 01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 01. August 2012 / Br J Dermatol The tumour suppressor p53 is frequently nonfunctional in Sezary syndrome B. Lamprecht S. Kreher M. Moebs W. Sterry B. Doerken M. Janz C. Assaf S. Mathas 01. Januar 2000 / Gene Funct Dis Y-box factor YB-1 is associated with the centrosome during mitosis M. Janz K. Juerchott L. Karawajew H.D. Royer 01. Januar 2000 / Canc Res Anti-CD20-and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways S. Mathas A. Rickers K. Bommert B. Doerken M.Y. Mapara 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel Seitennummerierung Aktuelle Seite 1 Seite 2 Seite 3 Nächste Seite Next › Letzte Seite Last »
11. April 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert
15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
01. August 2012 / Br J Dermatol The tumour suppressor p53 is frequently nonfunctional in Sezary syndrome B. Lamprecht S. Kreher M. Moebs W. Sterry B. Doerken M. Janz C. Assaf S. Mathas
01. Januar 2000 / Gene Funct Dis Y-box factor YB-1 is associated with the centrosome during mitosis M. Janz K. Juerchott L. Karawajew H.D. Royer
01. Januar 2000 / Canc Res Anti-CD20-and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways S. Mathas A. Rickers K. Bommert B. Doerken M.Y. Mapara
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel